| pubmed-article:21317876 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0442038 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0677930 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C1336956 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0086035 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:21317876 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:21317876 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21317876 | pubmed:dateCreated | 2011-6-1 | lld:pubmed |
| pubmed-article:21317876 | pubmed:abstractText | Downregulation of the immune system facilitates tumor progression at different stages of cutaneous melanoma. Sentinel nodes, the first lymph nodes on lymphatics draining directly from a primary melanoma, are immune downregulated by tumor-generated immunosuppressive cytokines, including interleukin-10 (IL-10). To better understand the kinetics of sentinel node suppression, we investigated IL-10 expression by melanoma cells and tumor-associated macrophages and lymphocytes at different stages of primary melanoma evolution. We used reverse-transcriptase in situ PCR to identify the cellular sources of IL-10 mRNA in 39 melanomas. IL-10 mRNA was identified in tumor cells of 2 of 6 melanomas in situ (33%), of 17 of 21 invasive melanomas (81%) and of 11 of 12 metastatic melanomas (92%). Higher IL-10 expression correlates with tumor progression, with differences between melanoma in situ, invasive melanoma and metastatic melanoma. In primary melanomas, the IL-10 mRNA content of tumor cells correlates with Clark's level. There was significantly more IL-10 mRNA in vertical growth-phase melanoma cells than in radial growth-phase cells. In a logistic regression model, moderate-to-high IL-10 mRNA expression by tumor cells was significantly associated with vertical growth-phase melanoma. IL-10 mRNA was detected in melanoma-associated macrophages and lymphocytes. In invasive melanomas, IL-10 mRNA reactivity of macrophages decreased as Clark's level increased. Alterations of immunity by IL-10 derived from melanoma cells and melanoma-associated macrophages and lymphocytes potentially facilitate evolution of the primary melanoma and render regional lymph nodes susceptible to metastases. | lld:pubmed |
| pubmed-article:21317876 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21317876 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21317876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21317876 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21317876 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21317876 | pubmed:issn | 1530-0285 | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:ItakuraEijunE | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:CochranAlista... | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:WenDuan-RenDR | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:HuangRong-Ron... | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:PaulEberhardE | lld:pubmed |
| pubmed-article:21317876 | pubmed:author | pubmed-author:WünschPeter... | lld:pubmed |
| pubmed-article:21317876 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21317876 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:21317876 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21317876 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21317876 | pubmed:pagination | 801-9 | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:meshHeading | pubmed-meshheading:21317876... | lld:pubmed |
| pubmed-article:21317876 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21317876 | pubmed:articleTitle | IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. | lld:pubmed |
| pubmed-article:21317876 | pubmed:affiliation | Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. itakura@ucla.edu | lld:pubmed |
| pubmed-article:21317876 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21317876 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:3586 | entrezgene:pubmed | pubmed-article:21317876 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21317876 | lld:entrezgene |
